In the dynamic landscape of healthcare innovation, few companies stand out as champions of change. As a venture capital firm deeply committed to addressing the rising costs of healthcare, we’re thrilled to announce our continued investment in VenoStent.
The stellar results from their feasibility study, their unwavering focus on clinical excellence and milestone execution, and the efficiency of their lean team have reaffirmed our unwavering belief in their path toward success.
Our journey alongside VenoStent kicked off in 2021 when we led the Seed round that went toward funding their first-in-human feasibility study. The results have been nothing short of remarkable. VenoStent’s product, SelfWrap, designed to improve vascular surgery outcomes for hemodialysis patients, has shown exceptional potential in real-world patient scenarios.
Lining up the puzzle pieces
As an early-stage startup, numerous things need to fall into place, and the order in which they need to happen is rarely straightforward. We have been incredibly impressed by VenoStent team’s ability to prioritize and strategize their milestones.
The company has received staged IDE approval, prepared the first few clinical enrollment sites, diligently gone through regulatory compliance, and prepared to establish a manufacturing facility towards FDA auditability.
Given all the pieces in place, the latest Series A funding, led by Good Growth Capital and IAG Capital Partners, will get the ball rolling for the next key stage—the pivotal trial execution.
True to their mission
Our partnership with VenoStent over the past two years has reinforced our confidence in their mission. Here’s why we invested in VenoStent in 2021, and at the core, the market-driven opportunity in chronic kidney diseases, hemodialysis, and specifically vascular surgery has persisted.
End-stage kidney disease is non-reversible, requiring patients to undergo dialysis or kidney transplants; the latter is not readily available and not always compatible. Hemodialysis makes up 90% of the dialysis in the United States and requires vascular access surgery to prepare the body for the rigors of dialysis. However, that procedure has a roughly 60% one-year failure rate—less than a coin flip’s chance of success. VenoStent’s device is designed to reduce vascular surgery failure rate for hemodialysis patients, improving the quality and length of life for patients, while simultaneously reducing the cost of care.
Having the privilege of working closely with VenoStent’s team, we have become even more convinced that the market is actively looking for a game-changing solution in an area that has seen little protocol changes over the years. As we tread this path together, we look forward to witnessing the profound transformation VenoStent has the power to ignite.